The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.
Brain metastases are the most frequent cancer in the central nervous system, being ten times more common than primary brain tumors. Patients generally have a poor outcome with a median survival of 4 months after diagnosis of the metastases. Therapeutic options include surgery, stereotactic, radiosurgery, whole-brain radiotherapy (WBRT), and chemotherapy. Patients with a limited number of brain metastases and well-controlled systemic cancer benefit from brain metastases-specific therapies, including surgery, radiosurgery, and conventional radiation. The role of chemotherapy for brain metastases remains limited. There is concern about drug delivery because of the blood-brain barrier. However, higher response rates are noted with initial therapies, suggesting that part of the poor response rate may be related to the late onset of brain metastases and the use of second- and third-line regimens. Recent studies have demonstrated objective responses with systemic therapy in a variety of cancer types, especially when combined with WBRT. Individual therapeutic strategies for central nervous system metastases must be chosen based on performance status, the extent of intracranial disease, and the chemosensitivity of the underlying tumor, as well as the control of the systemic cancer. In this article we review important prognostic factors and challenges in using chemotherapy. We specifically review recent advances in the treatment of brain metastases from breast and lung cancer as well as melanoma. Future treatment advances will require a multidisciplinary approach integrating surgical, radiation, and chemotherapeutic options to improve neurological function and quality of life, rather than just focusing on survival endpoints.
Walbert
Tobias
T
Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
Gilbert
Mark R
MR
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D016371:Cranial Irradiation; D019317:Evidence-Based Medicine; D006801:Humans; D019635:Neurosurgical Procedures; D018579:Patient Selection; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents
J Neurooncol. 2006 Jul;78(3):277-80
16614943
Eur J Cancer. 1993;29A(12):1696-9
7691116
J Clin Oncol. 2003 Jul 1;21(13):2551-7
12829675
Melanoma Res. 2003 Feb;13(1):97-103
12569292
J Clin Oncol. 2000 Oct 1;18(19):3400-8
11013281
Cancer. 2004 Oct 15;101(8):1760-6
15386311
Cancer. 1981 Jul 15;48(2):384-94
7237407
Ann Oncol. 2001 Feb;12(2):249-54
11300333
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302
10661335
Ann Oncol. 1993 Aug;4(7):579-83
8395873
Br J Cancer. 1990 Jan;61(1):147-50
2153393
J Clin Oncol. 2007 Jun 1;25(16):2306-12
17538177
J Clin Oncol. 1999 Nov;17(11):3522-30
10550150
Ann Oncol. 2006 Jun;17(6):952-6
16565212
Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
10098435
Lung Cancer. 1998 May;20(2):85-91
9711526
J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8
11935312
Oncology. 2003;64(1):28-35
12457029
CNS Drugs. 2002;16(5):325-38
11994022
J Neurooncol. 1994;20(2):121-39
7807190
Ann Oncol. 2003 Jul;14(7):1072-7
12853349
Cancer. 1990 Nov 1;66(9):1873-8
2224783
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
9128946
Cancer. 2002 May 15;94(10):2698-705
12173339
J Clin Oncol. 2002 Sep 1;20(17):3644-50
12202665
Ann Oncol. 2004 Jul;15(7):1042-7
15205197
Ann Oncol. 2006 Sep;17(9):1412-7
16790516
Med Oncol. 2000 Nov;17(4):279-86
11114706
Clin Cancer Res. 2009 Feb 15;15(4):1452-9
19228746
Curr Oncol Rep. 2001 Nov;3(6):463-6
11595113
Cancer Invest. 2002;20(3):293-302
12025223
Cancer Treat Rep. 1981 Sep-Oct;65(9-10):811-4
6268295
Eur J Cancer. 2003 Jun;39(9):1271-6
12763216
Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7
11164720
J Clin Oncol. 2005 Mar 1;23(7):1530-7
15735128
Cancer. 2005 Jun 15;103(12):2590-7
15861414
Lung Cancer. 2005 Nov;50(2):247-54
16039010
Lung Cancer. 2004 Oct;46(1):107-11
15364138
Ann Oncol. 2001 Jan;12(1):59-67
11249050
Arch Neurol. 1988 Jul;45(7):741-4
3390029
Lung Cancer. 1998 May;20(2):93-8
9711527
J Clin Oncol. 2006 May 1;24(13):2079-83
16648509
Cancer. 2008 Nov 1;113(9):2524-31
18798231
J Clin Oncol. 2004 Jun 1;22(11):2101-7
15169796
Clin Cancer Res. 2007 Mar 15;13(6):1648-55
17363517
J Clin Oncol. 1989 Jul;7(7):916-22
2544685
Cancer. 1986 Aug 15;58(4):832-9
3755076
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
10863071
Anticancer Drugs. 2007 Jan;18(1):23-8
17159499
Cancer. 1992 Feb 15;69(4):972-80
1735089
Oncology. 2000 Nov;59(4):291-5
11096340
Cancer. 1996 Oct 15;78(8):1781-8
8859192
Ann Oncol. 2006 Oct;17(10):1592-7
17005632
J Clin Oncol. 2004 Sep 1;22(17):3608-17
15337811
J Neurooncol. 2005 Jan;71(1):61-5
15719277
J Neurooncol. 2001 Jul;53(3):259-65
11718258
Br J Cancer. 2007 Jan 15;96(1):44-8
17146474
Cancer. 1999 Apr 1;85(7):1599-605
10193952
J Clin Oncol. 2004 Jul 15;22(14):2865-72
15254054
Cancer Treat Res. 2007;136:1-21
18078262
Eur J Cancer. 2002 Sep;38(13):1724-9
12175688
Cancer. 2006 Jun 1;106(11):2445-51
16639739
Neurol Clin. 2003 Feb;21(1):1-23, vii
12690643
Oncologist. 2007 Jul;12(7):766-73
17673608
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Cancer. 1979 Nov;44(5):1913-8
498057
Oncologist. 2004;9(1):68-79
14755016
Cancer. 2006 Sep 15;107(6):1348-54
16909414